Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

NCT07037004 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Sarcomatoid Renal Cell Carcinoma
Stage II Renal Cell Cancer AJCC v8
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Clostridium butyricum CBM588 Strain
PROCEDURE: Computed Tomography
BIOLOGICAL: Pembrolizumab

Sponsor

City of Hope Medical Center

Collaborators

[object Object]